🇺🇸 FDA
Patent

US 11130777

Crystalline phases of 5,6-dichloro-2-(isopropylamino)-(1-beta-L-ribofuranosyl)-1H-benzimidazole

granted A61KA61K31/7056A61P

Quick answer

US patent 11130777 (Crystalline phases of 5,6-dichloro-2-(isopropylamino)-(1-beta-L-ribofuranosyl)-1H-benzimidazole) held by Takeda Pharmaceutical Company Limited expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Sep 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/7056, A61P, A61P31/22